155 related articles for article (PubMed ID: 9079651)
1. Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells.
Koli KM; Ramsey TT; Ko Y; Dugger TC; Brattain MG; Arteaga CL
J Biol Chem; 1997 Mar; 272(13):8296-302. PubMed ID: 9079651
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.
Fanayan S; Firth SM; Butt AJ; Baxter RC
J Biol Chem; 2000 Dec; 275(50):39146-51. PubMed ID: 10993898
[TBL] [Abstract][Full Text] [Related]
3. Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells.
Ammanamanchi S; Tillekeratne MP; Ko TC; Brattain MG
Cancer Res; 2004 Apr; 64(7):2509-15. PubMed ID: 15059906
[TBL] [Abstract][Full Text] [Related]
4. Autocrine and exogenous transforming growth factor beta control cell cycle inhibition through pathways with different sensitivity.
Wang J; Sergina N; Ko TC; Gong J; Brattain MG
J Biol Chem; 2004 Sep; 279(38):40237-44. PubMed ID: 15271980
[TBL] [Abstract][Full Text] [Related]
5. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Ohmori T; Yang JL; Price JO; Arteaga CL
Exp Cell Res; 1998 Dec; 245(2):350-9. PubMed ID: 9851876
[TBL] [Abstract][Full Text] [Related]
6. Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells.
Mazars P; Barboule N; Baldin V; Vidal S; Ducommun B; Valette A
FEBS Lett; 1995 Apr; 362(3):295-300. PubMed ID: 7729516
[TBL] [Abstract][Full Text] [Related]
7. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
Herman ME; Katzenellenbogen BS
J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
[TBL] [Abstract][Full Text] [Related]
8. Distinct roles of transforming growth factor-β signaling and transforming growth factor-β receptor inhibitor SB431542 in the regulation of p21 expression.
Koo BH; Kim Y; Je Cho Y; Kim DS
Eur J Pharmacol; 2015 Oct; 764():413-423. PubMed ID: 26187313
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
Guo Y; Kyprianou N
Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
[TBL] [Abstract][Full Text] [Related]
10. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling.
Fanayan S; Firth SM; Baxter RC
J Biol Chem; 2002 Mar; 277(9):7255-61. PubMed ID: 11751851
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.
Buck MB; Pfizenmaier K; Knabbe C
Mol Endocrinol; 2004 Jul; 18(7):1643-57. PubMed ID: 15056732
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
Gong J; Ammanamanchi S; Ko TC; Brattain MG
Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
[TBL] [Abstract][Full Text] [Related]
13. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells.
Kim SG; Kim SN; Jong HS; Kim NK; Hong SH; Kim SJ; Bang YJ
Oncogene; 2001 Mar; 20(10):1254-65. PubMed ID: 11313870
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors.
Salatino M; Labriola L; Schillaci R; Charreau EH; Elizalde PV
Exp Cell Res; 2001 Apr; 265(1):152-66. PubMed ID: 11281653
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.
Lynch MA; Petrel TA; Song H; Knobloch TJ; Casto BC; Ramljak D; Anderson LM; DeGroff V; Stoner GD; Brueggemeier RW; Weghorst CM
Gene Expr; 2001; 9(4-5):157-71. PubMed ID: 11444526
[TBL] [Abstract][Full Text] [Related]
16. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Arteaga CL; Koli KM; Dugger TC; Clarke R
J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
[TBL] [Abstract][Full Text] [Related]
17. A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells.
Ko Y; Koli KM; Banerji SS; Li W; Zborowska E; Willson JK; Brattain MG; Arteaga CL
Int J Oncol; 1998 Jan; 12(1):87-94. PubMed ID: 9454891
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
Yan Z; Deng X; Friedman E
J Biol Chem; 2001 Jan; 276(2):1555-63. PubMed ID: 11029459
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
20. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
